Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kezar Life Sciences (KZR) Equity Ratio (2021 - 2025)

Kezar Life Sciences' Equity Ratio history spans 5 years, with the latest figure at 0.82 for Q1 2025.

  • For Q1 2025, Equity Ratio fell 3.12% year-over-year to 0.82; the TTM value through Mar 2025 reached 0.82, down 3.12%, while the annual FY2024 figure was 0.81, 4.69% down from the prior year.
  • Equity Ratio for Q1 2025 was 0.82 at Kezar Life Sciences, up from 0.81 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.94 in Q2 2022 and bottomed at 0.81 in Q4 2024.
  • The 5-year median for Equity Ratio is 0.89 (2023), against an average of 0.88.
  • The largest annual shift saw Equity Ratio increased 1.79% in 2022 before it dropped 6.77% in 2023.
  • A 5-year view of Equity Ratio shows it stood at 0.9 in 2021, then decreased by 0.28% to 0.9 in 2022, then dropped by 5.89% to 0.85 in 2023, then dropped by 4.69% to 0.81 in 2024, then increased by 1.83% to 0.82 in 2025.
  • Per Business Quant, the three most recent readings for KZR's Equity Ratio are 0.82 (Q1 2025), 0.81 (Q4 2024), and 0.82 (Q3 2024).